Related Experiment Videos
Liver disease and the hypothalamic pituitary gonadal axis
Seminars in Liver Disease
|February 1, 1985
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Treatment of hepatitis C virus in elderly persons with interferon alpha.
The journals of gerontology. Series A, Biological sciences and medical sciences·1995
The "pseudo-cholangiocarcinoma sign" in patients with cavernous transformation of the portal vein and its effect on the serum alkaline phosphatase and bilirubin levels.
The American journal of gastroenterology·1995
Source of oxygen free radicals produced by rat hepatocytes during postanoxic reoxygenation.
Biochimica et biophysica acta·1995
Cavernous transformation of the portal vein: a common manifestation of Behçet's disease.
The American journal of gastroenterology·1995
The ABCs of chronic hepatitis: reason out of confusion.
The Journal of the Oklahoma State Medical Association·1995
Molecular Mechanisms of Progressive Familial Intrahepatic Cholestasis.
Seminars in liver disease·2026
Metabolic Dysfunction-Associated Steatotic Liver Disease Reprograms the Hepatic Metastatic Niche.
Seminars in liver disease·2026
Advances in Extracorporeal Liver Support.
Seminars in liver disease·2026
Toward Precision Medicine in MASLD: Evolution of Disease Subtyping.
Seminars in liver disease·2026
MASH-Associated T Cell Activation and Neuroinflammation: Evidence for a Hepatosystemic Immune Axis.
Seminars in liver disease·2026
Endothelial Cell Therapy for the Acute and Chronic Liver Disease.
Seminars in liver disease·2026
Development of cecal volvulus after redo pancreas transplantation.
Journal of surgical case reports·2026
Primary Diffuse Large B-Cell Lymphoma of the External Auditory Canal with Extensive Local Extension: A Case Report and Literature Review.
Iranian journal of otorhinolaryngology·2026
Comparison of variably specific Bruton tyrosine kinase inhibitors on platelet aggregation mediated by Fcγ receptor (FcγR) IIa, glycoprotein VI, and platelet endothelial aggregation receptor (PEAR) 1: implications for Bruton tyrosine kinase inhibitors as antithrombotic therapy.
Research and practice in thrombosis and haemostasis·2026